A Phase 3 interventional study of Apremilast in Psoriasis, sponsored by Amgen. Terminated at 50 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 18th largest by enrollment, is one of 6 that started in 2019, is one of 18 in phase 3, and was the 32nd registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 27 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 167 (68%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 36 (60%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 33rd largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2019, is one of 32 in phase 3, and was the 53rd registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy.
The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must satisfy the following criteria to be enrolled in the study:
At the time of study entry, and at any time during the study when a female subject of childbearing potential's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding abstinence or contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.
Females of childbearing potential must have a negative pregnancy test at each visit. All FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
Option 1: Any one of the following effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy;
OR
Option 2: Male or female condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method:
(a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
NOTE: Option 2 may not be acceptable as a contraception option in all countries per local guidelines/regulations.
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Subject plans concurrent use of the following therapies that may have a possible effect on psoriasis.
i. Etanercept (or biosimilar) treatment ii. Adalimumab (or biosimilar) treatment iii. Other TNF or interleukin (IL)-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) iv. Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) c) Use of any drug other than apremilast
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with a weight between 20 kg to \< 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
Drug: Apremilast
Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
Also known as: CC-10004, Otezla
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product. Serious TEAEs were those that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability/incapacity, led to a congenital anomaly/birth defect, or were considered other important medical events. Apremilast-related TEAEs were TEAEs assessed by the investigator as related to the study drug. Severe TEAEs are events causing significant discomfort or pain, requiring medical intervention or drug therapy, and interfering with activities of daily living.
Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Number of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.
Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Change From Baseline in Body Weight
Change from baseline in body weight was reported.
Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Change From Baseline in Height
Change from baseline in height of the participants was reported.
Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Change From Baseline in Body Mass Index (BMI)
Change from baseline in BMI was reported.
Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Number of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Number of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response
The sPGA is the assessment of whole body psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. sPGA response is defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline in core study.
Time frame: Weeks 0, 52, 104, 156, and 208.
Participants were enrolled into this study at sites in Belgium, Canada, Czech Republic, France, Israel, Italy, Russia, Spain, and the United States. This study was conducted between 20 December 2019 and 12 December 2025.
| Milestone | Apremilast |
|---|---|
| Started | 160 |
| Received at least one dose of apremilast | 160 |
| Completed | 22 |
| Not completed | 138 |
| Withdrew: Non-compliance with study drug | 1 |
| Withdrew: Study terminated by sponsor | 27 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by parent/guardian | 15 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Lack of efficacy | 10 |
| Withdrew: Apremilast commercially available in the country for the pediatric patients | 8 |
| Withdrew: Turned 18 years old | 54 |
| Withdrew: Adverse event | 4 |
| Withdrew: Miscellaneous | 6 |
An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product. Serious TEAEs were those that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability/incapacity, led to a congenital anomaly/birth defect, or were considered other important medical events. Apremilast-related TEAEs were TEAEs assessed by the investigator as related to the study drug. Severe TEAEs are events causing significant discomfort or pain, requiring medical intervention or drug therapy, and interfering with activities of daily living.
| Participants | Apremilast |
|---|---|
| TEAE | 86 |
| Serious TEAE | 5 |
| Apremilast-related TEAE | 18 |
| Severe TEAE | 5 |
| Apremialst-related Serious TEAE | 1 |
| TEAE Leading to Drug Interruption | 11 |
| TEAE Leading to Drug Withdrawal | 6 |
| TEAE Leading to Death | 0 |
The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.
| Participants | Apremilast |
|---|---|
| Number of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS) | 0 |
Change from baseline in body weight was reported.
| Kilograms (kg) | Apremilast |
|---|---|
| Change From Baseline in Body Weight | 7.46 ± 7.915 |
Change from baseline in height of the participants was reported.
| centimeter (cm) | Apremilast |
|---|---|
| Change From Baseline in Height | 7.67 ± 8.277 |
Change from baseline in BMI was reported.
| kilograms per meter square | Apremilast |
|---|---|
| Change From Baseline in Body Mass Index (BMI) | 1.16 ± 2.082 |
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
| Participants | Apremilast |
|---|---|
| Breast Growth — Stage 1 | 18 |
| Breast Growth — Stage 2 | 14 |
| Breast Growth — Stage 3 | 9 |
| Breast Growth — Stage 4 | 18 |
| Breast Growth — Stage 5 | 26 |
| Breast Growth — Missing | 0 |
| Pubic Hair Growth — Stage 1 | 19 |
| Pubic Hair Growth — Stage 2 | 14 |
| Pubic Hair Growth — Stage 3 | 9 |
| Pubic Hair Growth — Stage 4 | 17 |
| Pubic Hair Growth — Stage 5 | 26 |
| Pubic Hair Growth — Missing | 0 |
| Other Changes — Stage 1 | 19 |
| Other Changes — Stage 2 | 14 |
| Other Changes — Stage 3 | 11 |
| Other Changes — Stage 4 | 15 |
| Other Changes — Stage 5 | 26 |
| Other Changes — Missing | 0 |
The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.
| Participants | Apremilast |
|---|---|
| Testes Growth — Stage 1 | 20 |
| Testes Growth — Stage 2 | 7 |
| Testes Growth — Stage 3 | 11 |
| Testes Growth — Stage 4 | 14 |
| Testes Growth — Stage 5 | 23 |
| Testes Growth — Missing | 0 |
| Penis Growth — Stage 1 | 20 |
| Penis Growth — Stage 2 | 7 |
| Penis Growth — Stage 3 | 12 |
| Penis Growth — Stage 4 | 12 |
| Penis Growth — Stage 5 | 24 |
| Penis Growth — Missing | 0 |
| Pubic Hair Growth — Stage 1 | 19 |
| Pubic Hair Growth — Stage 2 | 9 |
| Pubic Hair Growth — Stage 3 | 10 |
| Pubic Hair Growth — Stage 4 | 15 |
| Pubic Hair Growth — Stage 5 | 22 |
| Pubic Hair Growth — Missing | 0 |
| Other Changes — Stage 1 | 21 |
| Other Changes — Stage 2 | 7 |
| Other Changes — Stage 3 | 9 |
| Other Changes — Stage 4 | 14 |
| Other Changes — Stage 5 | 23 |
| Other Changes — Missing | 1 |
The sPGA is the assessment of whole body psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. sPGA response is defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline in core study.
| percentage of participants | Apremilast |
|---|---|
| Week 0 | 60 |
| Week 52 | 57.8 |
| Week 104 | 65.9 |
| Week 156 | 67.3 |
| Week 208 | 65.2 |
Collected over Week 0 through end of Long-term Extension Phase (up to 208 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apremilast 20 mg BID | 0/74 (0%) | 2/74 (2.7%) | 27/74 (36.5%) |
| Apremilast 30 mg BID | 0/86 (0%) | 3/86 (3.5%) | 25/86 (29.1%) |
| Apremilast BID | 0/160 (0%) | 5/160 (3.1%) | 52/160 (32.5%) |
| Event | Apremilast 20 mg BID | Apremilast 30 mg BID | Apremilast BID |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/74 | 0/86 | 1/160 |
| Acute kidney injuryRenal and urinary disorders | 1/74 | 0/86 | 1/160 |
| PhimosisCongenital, familial and genetic disorders | 0/74 | 1/86 | 1/160 |
| HeadacheNervous system disorders | 0/74 | 1/86 | 1/160 |
| Suicidal ideationPsychiatric disorders | 0/74 | 1/86 | 1/160 |
| Event | Apremilast 20 mg BID | Apremilast 30 mg BID | Apremilast BID |
|---|---|---|---|
| InfluenzaInfections and infestations | 6/74 | 1/86 | 7/160 |
| PsoriasisSkin and subcutaneous tissue disorders | 4/74 | 6/86 | 10/160 |
| Abdominal painGastrointestinal disorders | 5/74 | 1/86 | 6/160 |
| VomitingGastrointestinal disorders | 5/74 | 4/86 | 9/160 |
| COVID-19Infections and infestations | 5/74 | 4/86 | 9/160 |
| HeadacheNervous system disorders | 5/74 | 4/86 | 9/160 |
| Respiratory tract infection viralInfections and infestations | 3/74 | 5/86 | 8/160 |
| Viral upper respiratory tract infectionInfections and infestations | 4/74 | 4/86 | 8/160 |
Long-term Extension Treatment Population: all participants who received at least one dose of apremilast.
| Age, Continuous(years) | Apremilast |
|---|---|
| Mean | 12.9 ± 3.13 |
| Sex: Female, Male(Participants) | Apremilast |
|---|---|
| Female | 85 |
| Male | 75 |
| Ethnicity (NIH/OMB)(Participants) | Apremilast |
|---|---|
| Hispanic or Latino | 19 |
| Not Hispanic or Latino | 136 |
| Unknown or Not Reported | 5 |
| Race (NIH/OMB)(Participants) | Apremilast |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 149 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Body Weight(kilograms (kg)) | Apremilast |
|---|---|
| Mean | 51.70 ± 20.84 |
| Height(centimeters (cm)) | Apremilast |
|---|---|
| Mean | 155 ± 16.56 |
| Body Mass Index(kilograms per meter square) | Apremilast |
|---|---|
| Mean | 20.76 ± 5.04 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Dec 2019 to primary completion in Oct 2025, 70 months.
Results were first posted in Nov 2026, 1 year after primary completion. A results delay was requested in Aug 2023.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast